Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 121

1.

Preliminary clinical assessment of dynamic 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for evaluating the clinicopathological grade in patients with non-Hodgkin's lymphoma: a prospective study.

Shinya T, Otomi Y, Dimitrakopoulou-Strauss A, Kubo M, Kondo M, Otomo M, Terazawa K, Bando Y, Harada M.

Nucl Med Commun. 2020 Jan;41(1):26-33. doi: 10.1097/MNM.0000000000001120.

PMID:
31800508
2.

Imaging Features of Multiple Myeloma Extramedullary Lesions in the Liver with 18F-FDG PET/CT, Contrast-Enhanced CT and MRI.

Papamichail D, Hog R, Goldschmidt H, Dimitrakopoulou-Strauss A.

Diagnostics (Basel). 2019 Nov 7;9(4). pii: E179. doi: 10.3390/diagnostics9040179.

3.

Neoadjuvant Pazopanib Treatment in High-Risk Soft Tissue Sarcoma: A Quantitative Dynamic 18F-FDG PET/CT Study of the German Interdisciplinary Sarcoma Group.

Sachpekidis C, Karampinis I, Jakob J, Kasper B, Nowak K, Pilz L, Attenberger U, Gaiser T, Derigs HG, Schwarzbach M, Hohenberger P, Dimitrakopoulou-Strauss A, Ronellenfitsch U.

Cancers (Basel). 2019 Jun 8;11(6). pii: E790. doi: 10.3390/cancers11060790.

4.

Multi-Path Dilated Residual Network for Nuclei Segmentation and Detection.

Wang EK, Zhang X, Pan L, Cheng C, Dimitrakopoulou-Strauss A, Li Y, Zhe N.

Cells. 2019 May 23;8(5). pii: E499. doi: 10.3390/cells8050499.

5.

DNA damage in human whole blood caused by radiopharmaceuticals evaluated by the comet assay.

Schmeiser HH, Muehlbauer KR, Mier W, Baranski AC, Neels O, Dimitrakopoulou-Strauss A, Schmezer P, Kratochwil C, Bruchertseifer F, Morgenstern A, Kopka K.

Mutagenesis. 2019 Sep 20;34(3):239-244. doi: 10.1093/mutage/gez007.

6.

Clinical significance of signs of autoimmune colitis in 18F-fluorodeoxyglucose positron emission tomography-computed tomography of 100 stage-IV melanoma patients.

Lang N, Dick J, Slynko A, Schulz C, Dimitrakopoulou-Strauss A, Sachpekidis C, Enk AH, Hassel JC.

Immunotherapy. 2019 Jun;11(8):667-676. doi: 10.2217/imt-2018-0146.

PMID:
31088239
7.

Preoperative Pazopanib in High-Risk Soft Tissue Sarcoma: Phase II Window-of Opportunity Study of the German Interdisciplinary Sarcoma Group (NOPASS/GISG-04).

Ronellenfitsch U, Karampinis I, Dimitrakopoulou-Strauss A, Sachpekidis C, Jakob J, Kasper B, Nowak K, Pilz L, Attenberger U, Gaiser T, Derigs HG, Schwarzbach M, Hohenberger P.

Ann Surg Oncol. 2019 May;26(5):1332-1339. doi: 10.1245/s10434-019-07183-4. Epub 2019 Mar 6.

PMID:
30843160
8.

Radiogenomic Analysis of F-18-Fluorodeoxyglucose Positron Emission Tomography and Gene Expression Data Elucidates the Epidemiological Complexity of Colorectal Cancer Landscape.

Vlachavas EI, Pilalis E, Papadodima O, Koczan D, Willis S, Klippel S, Cheng C, Pan L, Sachpekidis C, Pintzas A, Gregoriou V, Dimitrakopoulou-Strauss A, Chatziioannou A.

Comput Struct Biotechnol J. 2019 Jan 25;17:177-185. doi: 10.1016/j.csbj.2019.01.007. eCollection 2019.

9.

Quantitative dynamic 18F-fluorodeoxyglucose positron emission tomography/computed tomography before autologous stem cell transplantation predicts survival in multiple myeloma.

Sachpekidis C, Merz M, Kopp-Schneider A, Jauch A, Raab MS, Sauer S, Hillengass J, Goldschmidt H, Dimitrakopoulou-Strauss A.

Haematologica. 2019 Sep;104(9):e420-e423. doi: 10.3324/haematol.2018.213041. Epub 2019 Feb 14. No abstract available.

10.

18F-FDG PET/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab.

Sachpekidis C, Kopp-Schneider A, Hakim-Meibodi L, Dimitrakopoulou-Strauss A, Hassel JC.

Melanoma Res. 2019 Apr;29(2):178-186. doi: 10.1097/CMR.0000000000000541.

PMID:
30653029
11.

68Ga-PSMA-11 PET/CT in prostate cancer local recurrence: impact of early images and parametric analysis.

Sachpekidis C, Pan L, Hadaschik BA, Kopka K, Haberkorn U, Dimitrakopoulou-Strauss A.

Am J Nucl Med Mol Imaging. 2018 Oct 20;8(5):351-359. eCollection 2018.

12.

Can benign lymphoid tissue changes in 18F-FDG PET/CT predict response to immunotherapy in metastatic melanoma?

Sachpekidis C, Larribère L, Kopp-Schneider A, Hassel JC, Dimitrakopoulou-Strauss A.

Cancer Immunol Immunother. 2019 Feb;68(2):297-303. doi: 10.1007/s00262-018-2279-9. Epub 2018 Nov 26.

PMID:
30478475
13.

Correlation between genomic index lesions and mpMRI and 68Ga-PSMA-PET/CT imaging features in primary prostate cancer.

Kesch C, Radtke JP, Wintsche A, Wiesenfarth M, Luttje M, Gasch C, Dieffenbacher S, Pecqueux C, Teber D, Hatiboglu G, Nyarangi-Dix J, Simpfendörfer T, Schönberg G, Dimitrakopoulou-Strauss A, Freitag M, Duensing A, Grüllich C, Jäger D, Götz M, Grabe N, Schweiger MR, Pahernik S, Perner S, Herpel E, Roth W, Wieczorek K, Maier-Hein K, Debus J, Haberkorn U, Giesel F, Galle J, Hadaschik B, Schlemmer HP, Hohenfellner M, Bonekamp D, Sültmann H, Duensing S.

Sci Rep. 2018 Nov 12;8(1):16708. doi: 10.1038/s41598-018-35058-3.

14.

Retrospective Side Effect Profiling of the Metastatic Melanoma Combination Therapy Ipilimumab-Nivolumab Using Adverse Event Data.

Soldatos TG, Dimitrakopoulou-Strauss A, Larribere L, Hassel JC, Sachpekidis C.

Diagnostics (Basel). 2018 Oct 31;8(4). pii: E76. doi: 10.3390/diagnostics8040076.

15.

Monitoring of patients with metastatic melanoma treated with immune checkpoint inhibitors using PET-CT.

Dimitrakopoulou-Strauss A.

Cancer Immunol Immunother. 2019 May;68(5):813-822. doi: 10.1007/s00262-018-2229-6. Epub 2018 Aug 19. Review.

PMID:
30123922
16.

Longitudinal studies of the 18F-FDG kinetics after ipilimumab treatment in metastatic melanoma patients based on dynamic FDG PET/CT.

Sachpekidis C, Anwar H, Winkler JK, Kopp-Schneider A, Larribere L, Haberkorn U, Hassel JC, Dimitrakopoulou-Strauss A.

Cancer Immunol Immunother. 2018 Aug;67(8):1261-1270. doi: 10.1007/s00262-018-2183-3. Epub 2018 Jun 5.

PMID:
29872898
17.

Integrated analysis of dynamic FET PET/CT parameters, histology, and methylation profiling of 44 gliomas.

Röhrich M, Huang K, Schrimpf D, Albert NL, Hielscher T, von Deimling A, Schüller U, Dimitrakopoulou-Strauss A, Haberkorn U.

Eur J Nucl Med Mol Imaging. 2018 Jul;45(9):1573-1584. doi: 10.1007/s00259-018-4009-0. Epub 2018 May 7.

PMID:
29732524
18.

The role of interim 18F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma.

Sachpekidis C, Anwar H, Winkler J, Kopp-Schneider A, Larribere L, Haberkorn U, Hassel JC, Dimitrakopoulou-Strauss A.

Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1289-1296. doi: 10.1007/s00259-018-3972-9. Epub 2018 Feb 24.

PMID:
29478079
19.

Functional Imaging with 18F-FDG PET/CT and Diffusion Weighted Imaging (DWI) in Early Response Evaluation of Combination Therapy of Elotuzumab, Lenalidomide, and Dexamethasone in a Relapsed Multiple Myeloma Patient.

Sachpekidis C, Dimitrakopoulou-Strauss A, Delorme S, Goldschmidt H.

Diagnostics (Basel). 2017 Dec 15;7(4). pii: E61. doi: 10.3390/diagnostics7040061.

20.

Metastatic melanoma response to combination therapy with ipilimumab and vemurafenib.

Sachpekidis C, Hassel JC, Dimitrakopoulou-Strauss A.

Hell J Nucl Med. 2017 Sep-Dec;20(3):251-253. doi: 10.1967/s002449910611. Epub 2017 Nov 27.

Supplemental Content

Loading ...
Support Center